Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 1.9% – Should You Buy?

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) were up 1.9% during trading on Thursday . The stock traded as high as $6.08 and last traded at $6.03. Approximately 213,587 shares traded hands during trading, a decline of 27% from the average daily volume of 294,099 shares. The stock had previously closed at $5.92.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on EPRX shares. Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Stifel Nicolaus started coverage on Eupraxia Pharmaceuticals in a report on Thursday, May 21st. They set a “buy” rating and a $25.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, April 21st. Finally, Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eupraxia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $18.33.

Eupraxia Pharmaceuticals Stock Performance

The firm has a fifty day moving average of $6.97 and a 200-day moving average of $7.37. The firm has a market cap of $392.72 million, a P/E ratio of -5.75 and a beta of 0.97. The company has a quick ratio of 19.31, a current ratio of 19.31 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Research analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP bought a new position in Eupraxia Pharmaceuticals in the first quarter valued at about $5,137,000. DV Trading LLC bought a new position in Eupraxia Pharmaceuticals in the first quarter valued at about $1,998,000. Bank of America Corp DE boosted its holdings in Eupraxia Pharmaceuticals by 5.9% in the first quarter. Bank of America Corp DE now owns 268,221 shares of the company’s stock valued at $1,942,000 after acquiring an additional 14,900 shares during the last quarter. Ally Bridge Group NY LLC boosted its holdings in Eupraxia Pharmaceuticals by 66.0% in the first quarter. Ally Bridge Group NY LLC now owns 660,375 shares of the company’s stock valued at $4,781,000 after acquiring an additional 262,480 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in Eupraxia Pharmaceuticals by 33.2% in the first quarter. Royal Bank of Canada now owns 261,376 shares of the company’s stock valued at $1,893,000 after acquiring an additional 65,099 shares during the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.